Novartis Growth Should Normalize After Successful Turnaround -- Market Talk

Dow Jones
Oct 15

0859 GMT - Novartis completed a successful transformation and now outperforms its peers, but growth is set to normalize, Vontobel's Stefan Schneider writes. The Swiss pharma group's valuation now reflects its recent growth, though this happened more slowly than expected given nine straight quarters of Novartis beating and raising guidance, the analyst says. This is unlikely to be repeated when the company releases third-quarter results later this month, its first report since heart failure drug Entresto lost patent exclusivity, the analysts add. Novartis seems poised to deliver slower growth going forward, the analyst says. Vontobel cuts its recommendation on Novartis stock to hold from buy and keeps its target price of 112 Swiss francs. Shares fall 1.1% to 102.92 francs. (william.gray@wsj.com)

 

(END) Dow Jones Newswires

October 15, 2025 04:59 ET (08:59 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10